Compare CMTV & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMTV | PRLD |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | 139 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.7M | 207.5M |
| IPO Year | N/A | 2020 |
| Metric | CMTV | PRLD |
|---|---|---|
| Price | $42.00 | $3.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 34.2K | ★ 290.5K |
| Earning Date | N/A | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $29.53 | $0.61 |
| 52 Week High | $42.39 | $4.19 |
| Indicator | CMTV | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 84.45 | 53.86 |
| Support Level | $30.51 | $1.02 |
| Resistance Level | N/A | $4.10 |
| Average True Range (ATR) | 1.73 | 0.36 |
| MACD | 0.90 | -0.05 |
| Stochastic Oscillator | 93.97 | 38.48 |
Community Bancorp Inc is a holding company that provides a complete line of personal and business banking services with personal services and solutions. The company mainly offers Business banking, Commercial real estate lending, residential real estate lending, Retail credit, Municipal and Institutional Banking, and Retail Banking. The company's primary lending products are commercial, real estate, municipal, and consumer loans. The bank offers a complete line of personal and business products and services, along with offerings for non-profit organizations, municipalities, and local governments. The Firm also engages in lending activity outside the area of its branch network, through loan production offices in Burlington, Vermont, and Lebanon, New Hampshire.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.